Annual report
286A.TEDINET S100XUVY
Period2025-01-01 → 2025-12-31
Filed2026-03-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.7bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥19.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥18.1bn | 2023-01-01 → 2023-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.6bn | 2022-01-01 → 2022-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.4bn | 2025-01-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.8bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.9bn | 2023-01-01 → 2023-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥784m | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.1bn | 2025-01-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.1bn | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.8bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.1bn | 2023-01-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥980m | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.9bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥65.1bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥60.1bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥51.0bn | at 2023-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥42.6bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥43.3bn | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥41.2bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥21.8bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥19.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥11.8bn | at 2023-12-31d | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.1bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.2bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.1bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.7bn | at 2023-12-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.9bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥209m | 2023-01-01 → 2023-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.7bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥406m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.6bn | 2023-01-01 → 2023-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.4bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.8bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.5bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥6.3bn | 2023-01-01 → 2023-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.0bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥78.07 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.4 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.18 | 2023-01-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.8 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥76.75 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥63.12 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥574.26 | at 2025-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥507.67 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥362.04 | at 2023-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥324.44 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 31.5% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.3% | at 2023-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.7% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 14.4% | 2025-01-01 → 2025-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2023-01-01 → 2023-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.3% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,347 | at 2025-12-31 | Cons. | Number of employees |
| Employees | 833 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 769 | at 2023-12-31d | Cons. | Number of employees |
| Employees | 699 | at 2022-12-31d | Cons. | Number of employees |
| Revenue | ¥6.2bn | 2025-01-01 → 2025-12-31 | Standalone | Net sales |
| Revenue | ¥5.6bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥5.4bn | 2023-01-01 → 2023-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.0bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.4bn | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | ¥1.4bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | ¥1.4bn | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.1bn | 2023-01-01 → 2023-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥356m | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥827m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.2bn | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.4bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | ¥2.3bn | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | ¥1.8bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥709m | 2023-01-01 → 2023-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.3bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥565m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥40.7bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥36.0bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥29.2bn | at 2023-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥22.3bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.5bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥21.3bn | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥19.2bn | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥19.4bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥16.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥10.0bn | at 2023-12-31d | Standalone | Net assets |
| Net assets / equity | ¥9.3bn | at 2022-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.9bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥6.7bn | at 2024-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥63.87 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.56 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.72 | 2023-01-01 → 2023-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.24 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.91 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥62.79 | 2025-01-01 → 2025-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥57.4 | 2024-01-01 → 2024-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥541.59 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥477.26 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥333.28 | at 2023-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥310.1 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥265.41 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 47.5% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.2% | at 2023-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.7% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.5% | 2025-01-01 → 2025-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.7% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2023-01-01 → 2023-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.7% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 37,982,900 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 37,982,900 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,100 | at 2023-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,100 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,100 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 198 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 167 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 130 | at 2023-12-31d | Standalone | Number of employees |
| Employees | 117 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 119 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 70
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2025-01-01 → 2025-12-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-12-31 | 8 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-12-31 | ¥656m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-12-31 | ¥656m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-12-31 | ¥239m |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-12-31 | −¥6m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-12-31 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-12-31 | −¥1.4bn |
| Comprehensive Medical Management Support Businessreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥386m |
| Comprehensive Medical Management Support Businessreportable segment | employees | at 2025-12-31 | 319 pure |
| Comprehensive Medical Management Support Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥7.7bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥7.7bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥6m |
| Comprehensive Medical Management Support Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥2.4bn |
| Elderly Care Related Businessreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥541m |
| Elderly Care Related Businessreportable segment | employees | at 2025-12-31 | 910 pure |
| Elderly Care Related Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥8.9bn |
| Elderly Care Related Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥8.9bn |
| Elderly Care Related Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥530m |
| Specially Controlled Medical Device Businessreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥36m |
| Specially Controlled Medical Device Businessreportable segment | employees | at 2025-12-31 | 60 pure |
| Specially Controlled Medical Device Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥7.5bn |
| Specially Controlled Medical Device Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥7.5bn |
| Specially Controlled Medical Device Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥525m |
| —segment total | depreciation | 2025-01-01 → 2025-12-31 | ¥963m |
| —segment total | employees | at 2025-12-31 | 1289 pure |
| —segment total | revenue | 2025-01-01 → 2025-12-31 | ¥24.1bn |
| —segment total | revenue external | 2025-01-01 → 2025-12-31 | ¥24.1bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥6m |
| —segment total | segment profit | 2025-01-01 → 2025-12-31 | ¥3.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-01-01 → 2025-12-31 | ¥965m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-12-31 | ¥24.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-12-31 | ¥24.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥6m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-12-31 | ¥3.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-01-01 → 2024-12-31 | ¥380,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-12-31 | ¥63m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-12-31 | ¥63m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-12-31 | −¥140m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥70m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥9m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥9m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥1.2bn |
| Comprehensive Medical Management Support Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥309m |
| Comprehensive Medical Management Support Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥6.4bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥6.4bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥9m |
| Comprehensive Medical Management Support Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥2.8bn |
| Elderly Care Related Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥514m |
| Elderly Care Related Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥6.9bn |
| Elderly Care Related Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥6.9bn |
| Elderly Care Related Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥309m |
| Specially Controlled Medical Device Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥33m |
| Specially Controlled Medical Device Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥6.5bn |
| Specially Controlled Medical Device Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥6.5bn |
| Specially Controlled Medical Device Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥485m |
| —segment total | depreciation | 2024-01-01 → 2024-12-31 | ¥857m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥19.8bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥19.8bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥9m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-01-01 → 2024-12-31 | ¥857m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-12-31 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-12-31 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥9m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-12-31 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-12-31 | 8 pure |
| Comprehensive Medical Management Support Businessreportable segment | employees | at 2025-12-31 | 134 pure |
| Elderly Care Related Businessreportable segment | employees | at 2025-12-31 | 6 pure |
| —segment total | employees | at 2025-12-31 | 140 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,719
| Item | Context | Value | Unit |
|---|---|---|---|
| Retirement benefit expenses sga | Prior1YearDuration_NonConsolidatedMember | 90973000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration_NonConsolidatedMember | 114757000 | JPY |
| Depreciation sga | Prior1YearDuration_NonConsolidatedMember | 76104000 | JPY |
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 73927000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-03-27 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第21期(自 2025年１月１日 至 2025年12月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ユカリア | |
| Company name in english cover page | FilingDateInstant | EUCALIA Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 三沢 英生 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区霞が関三丁目２番５号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5501-2271 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員 IR室長 小川 一誠 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区霞が関三丁目２番５号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5501-2271 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 IR室長 小川 一誠 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E12328 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 286A0 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ユカリア | |
| Filer name in english | FilingDateInstant | EUCALIA Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2025-01-01 | |
| Current period end date | FilingDateInstant | 2025-12-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2025-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Comparative period end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |